As an opioid partial agonist, Buprenorphine CAS# 52485-79-7, has been a safe and effectual treatment for opioid addiction for over a decade. While there is treatment available through the use of full agonists like methadone, the benefit of treatment with buprenorphine is that it has less maximal effects in comparison. Low doses of buprenorphine initially produce adequate agonist effects to enable opioid-addicted patients to discontinue their misuse of opioids, without the adverse effects of significant and adverse withdrawal symptoms.
Additionally, the agonist effects of buprenorphine increase linearly with increasing doses of this drug, which carries a lower risk for patients of abuse, further addiction and negative side effects. The FDA approval of the implantable version of buprenorphine, also known as the brand name Probuphine is a recent indication of the success and viability of this opioid partial agonist.
On March 21, 2013 the Psychopharmacologic Drugs Advisory Committee approved these 80 milligram rod implants, voting 10-4 in favor of their approval. This treatment involves the placement of four to five rods under the patient’s skin for a treatment course of about four to six months. In comparison, the daily sublingual dose of buprenorphine, Suboxone, has a dose range from 12 to 16 milligrams, with a long term maintenance dose for patients of 4 to 8 milligrams. The advantage of the implants is a greater medication adherence for patients, as well as continued tolerable rehabilitative treatment.
Statistics regarding opioid addiction are startling and frightening. In 2010, 2 million people reported using prescription painkillers for nonmedical reasons for the first time within that year, which amounts to about 5,500 people a day abusing these treatments. As a medication designed to relieve acute pain, opioids work by reducing the intensity of the pain signals to the brain. Medications that fall within this class include hydrocodone (Vicodin), oxycodone (OxyContin, Percocet) and morphine (Kadian). The hydrocodone medications tend to be the most prescribed, often for medical and dental pain resulting from procedures. However, the use and subsequent misuse of these opioids have created a medical emergency worldwide. In the United States it is estimated that there are over 7 million people are addicted or physically dependent to some form of opiate or prescription pain killer. LGM Pharma offers API Buprenorphine for research and development purposes. Clients can be assured of quality products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk